![](https://www.eurekalert.org/images/EurekAlert-bluebg_Twitter_601X601.png)
Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation
CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven’t experienced improvement with chemotherapy treatments. But if this CAR …